Follicular Lymphoma Drugs Industry Research Report 2025

Summary

According to APO Research, The global Follicular Lymphoma Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Follicular Lymphoma Drugs include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma and Teva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Drugs.

The Follicular Lymphoma Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Follicular Lymphoma Drugs Segment by Company

Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma

Follicular Lymphoma Drugs Segment by Type

Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others

Follicular Lymphoma Drugs Segment by Administration Route
Injection
Oral

Follicular Lymphoma Drugs Segment by Administration Route
Injection
Oral

Follicular Lymphoma Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Follicular Lymphoma Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Follicular Lymphoma Drugs by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Anti-CD20 mAbs
2.2.3 Chemotherapy Agents
2.2.4 Kinase Inhibitor
2.2.5 Others
2.3 Follicular Lymphoma Drugs by Administration Route
2.3.1 Market Value Comparison by Administration Route (2020 VS 2024 VS 2031)
2.3.2 Injection
2.3.3 Oral
2.4 Assumptions and Limitations
3 Follicular Lymphoma Drugs Breakdown Data by Type
3.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2020-2025)
3.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031)
4 Follicular Lymphoma Drugs Breakdown Data by Administration Route
4.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2020-2025)
4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031)
5 Global Growth Trends
5.1 Global Follicular Lymphoma Drugs Market Perspective (2020-2031)
5.2 Global Follicular Lymphoma Drugs Growth Trends by Region
5.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2020-2025)
5.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2026-2031)
5.3 Follicular Lymphoma Drugs Market Dynamics
5.3.1 Follicular Lymphoma Drugs Industry Trends
5.3.2 Follicular Lymphoma Drugs Market Drivers
5.3.3 Follicular Lymphoma Drugs Market Challenges
5.3.4 Follicular Lymphoma Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Follicular Lymphoma Drugs Players by Revenue
6.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2020-2025)
6.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2020-2025)
6.2 Global Follicular Lymphoma Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Follicular Lymphoma Drugs Head Office and Area Served
6.4 Global Follicular Lymphoma Drugs Players, Product Type & Application
6.5 Global Follicular Lymphoma Drugs Manufacturers Established Date
6.6 Global Follicular Lymphoma Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Follicular Lymphoma Drugs Market Size (2020-2031)
7.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Follicular Lymphoma Drugs Market Size by Country (2020-2025)
7.4 North America Follicular Lymphoma Drugs Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Follicular Lymphoma Drugs Market Size (2020-2031)
8.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Follicular Lymphoma Drugs Market Size by Country (2020-2025)
8.4 Europe Follicular Lymphoma Drugs Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2020-2031)
9.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2020-2025)
9.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Follicular Lymphoma Drugs Market Size (2020-2031)
10.2 South America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Follicular Lymphoma Drugs Market Size by Country (2020-2025)
10.4 South America Follicular Lymphoma Drugs Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2020-2031)
11.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2020-2025)
11.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Roche
12.1.1 Roche Company Information
12.1.2 Roche Business Overview
12.1.3 Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.1.4 Roche Follicular Lymphoma Drugs Product Portfolio
12.1.5 Roche Recent Developments
12.2 Gilead Sciences
12.2.1 Gilead Sciences Company Information
12.2.2 Gilead Sciences Business Overview
12.2.3 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.2.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
12.2.5 Gilead Sciences Recent Developments
12.3 TG Therapeutics
12.3.1 TG Therapeutics Company Information
12.3.2 TG Therapeutics Business Overview
12.3.3 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.3.4 TG Therapeutics Follicular Lymphoma Drugs Product Portfolio
12.3.5 TG Therapeutics Recent Developments
12.4 Bayer
12.4.1 Bayer Company Information
12.4.2 Bayer Business Overview
12.4.3 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.4.4 Bayer Follicular Lymphoma Drugs Product Portfolio
12.4.5 Bayer Recent Developments
12.5 Secura Bio
12.5.1 Secura Bio Company Information
12.5.2 Secura Bio Business Overview
12.5.3 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.5.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
12.5.5 Secura Bio Recent Developments
12.6 Epizyme
12.6.1 Epizyme Company Information
12.6.2 Epizyme Business Overview
12.6.3 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.6.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
12.6.5 Epizyme Recent Developments
12.7 Eisai
12.7.1 Eisai Company Information
12.7.2 Eisai Business Overview
12.7.3 Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.7.4 Eisai Follicular Lymphoma Drugs Product Portfolio
12.7.5 Eisai Recent Developments
12.8 Acrotech Biopharma
12.8.1 Acrotech Biopharma Company Information
12.8.2 Acrotech Biopharma Business Overview
12.8.3 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.8.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
12.8.5 Acrotech Biopharma Recent Developments
12.9 Teva
12.9.1 Teva Company Information
12.9.2 Teva Business Overview
12.9.3 Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.9.4 Teva Follicular Lymphoma Drugs Product Portfolio
12.9.5 Teva Recent Developments
12.10 Eagle Pharmaceuticals
12.10.1 Eagle Pharmaceuticals Company Information
12.10.2 Eagle Pharmaceuticals Business Overview
12.10.3 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.10.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
12.10.5 Eagle Pharmaceuticals Recent Developments
12.11 MundiPharma
12.11.1 MundiPharma Company Information
12.11.2 MundiPharma Business Overview
12.11.3 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
12.11.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
12.11.5 MundiPharma Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings